コンテンツへスキップ
Merck

[Retigabine - a new antiepileptic drug with a different mechanism of action].

Postepy higieny i medycyny doswiadczalnej (Online) (2013-10-04)
Ewa Zwierzyńska, Bogusława Pietrzak
要旨

Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation. There is no interaction between retigabine and other antiepileptic drugs except lamotrigine. The drug has been registered as treatment of partial onset seizures with or without secondary generalization in adults. The efficacy of retigabine is being tested in other types of seizures and disorders characterized by neuronal hyperexcitability. Neuroprotective activity of retigabine is also being researched.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
レチガビン, ≥98% (HPLC)